ClinicalTrials.gg
CompletedNCT06418321Updated Feb 20, 2025

Early Identification of Age-related Hearing Impairment

An observational study in Hearing Loss, Age-Related, sponsored by Aalto University. Completed at 2 sites in Finland. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Aalto University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
49
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The need for future hearing rehabilitation is enormous. World Health Organization (WHO 2021) has estimated that by 2050, 2.5 billion people will have some degree of hearing loss, and 1/4 of them will require hearing rehabilitation. Currently, healthcare systems and processes are already overwhelmed and not adequately equipped to screen and diagnose this rapidly growing population suffering from hearing impairment. This study aims to investigate if the diagnostics of age-related hearing loss can be accelerated by involving patients in the hearing assessment process.

Read the detailed description

The investigational device used in the study is part of the Otoscreen hearing screening system that is developed by Aalto University.

The investigational device consists of the following parts:

  • Digital otoscope
  • User interface control unit.

The investigational device is designed to record high-quality images and videos of the eardrum and ear canal and guide users through a hearing screening test while collecting data from questionnaires, digital otoscopy, and audiometry.

The investigational device is used together with a CE-marked audiometer that is intended for hearing screening testing.

02

Conditions studied

  • Hearing Loss, Age-Related

Browse trials for

03

In context

Presbycusis

66 studies on the registry are indexed under Presbycusis; 21 are open to participants now.

This study's enrollment of 49 is below the median of 123 across 20 observational studies indexed under Presbycusis.

Browse Presbycusis studies →

Lead sponsor

Aalto University is the lead sponsor of 9 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Healthy volunteers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be able to understand Finnish or Swedish

Exclusion criteria

Exclusion Criteria:

  • Clinical diagnosis of hearing loss
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
49 participants (actual)
Patient registry
No

Groups and cohorts

  • Participant group 1: HUS Helsinki University Hospital

    Participants are tested with the investigational device and the gold-standard device.

    Device: Investigational device · Other: Audiometer · Device: Otomicroscopy · Other: REM (Real Ear Measurements)

  • Participant group 2: Aalto University

    Participants are tested with the investigational device.

    Device: Investigational device

Interventions

  • DeviceInvestigational device

    The participants' hearing status will be evaluated using the investigational device.

  • OtherAudiometer

    Participants' hearing thresholds are tested with an audiogram.

  • DeviceOtomicroscopy

    The status of the participants' ear canals and tympanic membranes are checked.

  • OtherREM (Real Ear Measurements)

    The acoustic properties of the participants' ears will be measured during the interventions.

06

What researchers measure

Primary outcomes

  1. Comparison between investigational device and gold-standard device (otomicroscope) findings.

    The investigators compare scored views to the outer ear canal and tympanic membrane.

    Time frame: From digital otoscopy to the interpretation of pictures (up to six months).

  2. Comparison between the automated hearing screening self-test result and the gold-standard hearing test result performed with clinical Audiometer by an Audiologist.

    The investigators compare pure tone averages.

    Time frame: From hearing tests to the comparison (up to six months).

Secondary outcomes

  1. Participant group 2: The usability of the investigational device.

    The usability of the investigational device will be assessed using a usability testing protocol. It includes subjective feedback from participants through interviews, questionnaires, and observation of device use. The usability will be assessed using the AttrakDiff method, a standardized questionnaire designed to measure the user's perception of a product's attractiveness, pragmatism, and overall appeal. This method provides insights into both the pragmatic and hedonic aspects of usability. AttrakDiff consists of multiple items scored on a semantic differential scale that consists of seven-step items whose poles are opposite adjectives (e.g. "confusing - clear", "unusual - ordinary", "good - bad"). Each set of adjective items is ordered into a scale of intensity. Usability testing will be conducted iteratively with the first group of participants (N=20), followed by modifications based on feedback. This iterative process will continue until no negative feedback is received.

    Time frame: From study appointment to the analysis of the results (up to six months).

  2. Participant group 1: REM measurements.

    If there is a difference between the automated hearing screening self-test result and the gold-standard hearing test result performed with clinical Audiometer, the investigators will look for the REM results if there is an explanation for the difference at the individual level.

    Time frame: From REM measurements to the analysis of the results (up to six months).

07

Study locations

2 sites
  • Aalto University
    Espoo, 02150, Finland
  • HUS Head and Neck Center
    Helsinki, 00130, Finland
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06418321
Lead sponsor
Aalto University
Collaborators
Business Finland, Helsinki University Central Hospital
Responsible party
Sponsor
First posted
May 17, 2024
Start date
Apr 4, 2024
Primary completion
Feb 12, 2025
Completion
Feb 12, 2025
Last update
Feb 20, 2025

Study contacts

Jouni Partanen, Prof.
principal investigator · Aalto University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion